Subtype | DHβE | MLA | Mecamylamine | α-Cbtx | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
n= | log(IC50/M) | nH | n= | log(IC50/M) | nH | n= | log(IC50 / M) | nH | n= | log(IC50/M) | nH | |
α7 (unlinked) | 3 | −5.2 ± 0.05 | −1.0 ± 0.1 | 3 | −8.7 ± 0.1 | −1.6 ± 0.2 | 3 | −5.6 ± 0.2 | 3 | −8.6 ± 0.1 | 2.4 ± 0.5 | |
α7-α7-α7-α7-α7 | 3 | −5.3 ± 0.07 | −0.8 ± 0.1 | 3 | −9.0 ± 0.1 | −1.6 ± 0.2 | 3 | −6.0 ± 0.2 | 3 | −8.6 ± 0.1 | 1.3 ± 0.8 | |
α7-α7-β2-α7-α7 | 3 | −5.4 ± 0.10 | −0.6 ± 0.1 | 3 | −8.9 ± 0.1 | −1.7 ± 0.1 | 3 | −6.0 ± 0.1 | 3 | −8.6 ± 0.1 | 1.8 ± 0.5 | |
α7-β2-α7-β2-α7 | 3 | −5.4 ± 0.10 | −0.7 ± 0.1 | 3 | −8.8 ± 0.1 | −1.8 ± 0.1 | 3 | −6.0 ± 0.2 | 3 | −8.5 ± 0.2 | 1.5 ± 0.6 |
Antagonist log IC50 and Hill slope (nH) values were derived by nonlinear least-squares curve fitting of the data shown in Fig. 5 to the Hill model. Pharmacological parameters obtained for each antagonist were statistically indistinguishable between all four groups of oocytes according to analysis with one-way analysis of variance.